Magenkarzinom – Was gibt’s Neues?

Literatur

• 1 Bang Y, Van Cutsem E, Feyereislova A. et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.  Lancet. 2010;  376 687-697
  Google Scholar
• 2 Cunningham D, Allum W, Stenning S. et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.  N Engl J Med. 2006;  335 11-20
  Google Scholar
• 3 Gebski V, Burmeister B, Smithers B. et al . Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.  Lancet. 2007;  8 226-234
  Google Scholar
• 4 Gotoda T, Yanagisawa A, Sasako M. et al . Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.  Gastric Cancer. 2000;  3 219-225
  Google Scholar
• 5 Heiss M, Murawa P, Koralewski P. et al . The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.  Int J Cancer. 2010;  127 2209-2221
  Google Scholar
• 6 Kinkel K, Lu Y, Both M, Warren R, Thoeni R. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.  Radiology. 2002;  224 748-756
  Google Scholar
• 7 Kwee R, Kwee T. Imaging in local staging of gastric cancer: a systematic review.  J Clin Oncol. 2007;  25 2107-2116
  Google Scholar
• 8 Lutz M, Wilke H, Wagener D. et al . Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.  J Clin Oncol. 2007;  25 2580-2585
  Google Scholar
• 9 Moehler M, Al-Batran S -E, Andus T. et al . S3-Leitlinie „Magenkarzinom“ – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032 – 009-OL).  Z Gastroenterol. 2011;  49 461-531
  Google Scholar
• 10 Moehler M, Mueller A, Trarbach T. et al . Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.  Ann Oncol. 2011;  22 1358-1366
  Google Scholar
• 11 Okines A, Norman A, McCloud P, Kang Y, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.  Ann Oncol. 2009;  20 1529-1534
  Google Scholar
• 12 Paoletti X, Oba K, Burzykowski T. et al . Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.  JAMA. 2010;  303 1729-1737
  Google Scholar
• 13 Puli S, Batapati Krishna Reddy J, Bechtold M, Antillon M, Ibdah J. How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review.  World J Gastroenterol. 2008;  14 4011-4019
  Google Scholar
• 14 SIGN .Management of oesophageal and gastric cancer. NHS. 2006
  Google Scholar
• 15 Ychou M, Boige V, Pignon J. et al . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.  J Clin Oncol. 2011;  29 1715-1721
  Google Scholar

PD Dr. med. Markus Möhler

I. Medizinische Klinik und Poliklinik
Universitätsmedizin der Johannes Gutenberg-Universität

Langenbeckstr. 1

55101 Mainz

Phone: 06131/176076

Fax: 06131/176472

Email: markus.moehler@unimedizin-mainz.de